PROFILE

오기욱 교수

Current status of therapeutic development for amyotrophic lateral sclerosis

To date, there are three approved treatments for ALS: riluzole, edaravon and toferson. Several clinical trials are currently ongoing to develop a treatment for ALS, with innovative approaches such as gene therapy and cell therapy being investigated

한양대학교 의과대학

EDUCATION

1996-2003 Bachelor of Medicine, College of Medicine, Hanyang University, Seoul, Korea.
2005-2012 Master of Science, College of Medicine, Hanyang university
2012-2015 Doctor of Philosophy, College of Medicine, Hanyang university

LICENSE

2008 Specialist license of Neurology, Ministry of health and welfare
2010 Basic life support Instructor (2010-12-9), American heart association
2010 Aviation Medical Examiner, Ministry of land, infrastructure and transport

PROFESSIONAL EXPERIENCES

2008-2011 Flight surgeon, Department of Neurology, Aerospace medical center, Republic of Korea Air Force
2011-2012 Fellowship, Department of Neurology, Hanyang University Hospital
2012-2013 Clinical Instructor, Department of Neurology, Hanyang University Hospital
2013-2016 Clinical Assistant Prof., Department of Neurology, Hanyang University Hospital
2016-2019 Assistant Prof., Department of Neurology, College of Medicine, Hanyang University
2019-present Associate Prof., Department of Neurology, College of Medicine, Hanyang University

PUBLICATIONS

1.Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R (R): lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study. JY Nam, S Chun, TY Lee, YJ Seo, KJ Kim, JS Park, WJ Sung, KW Oh, SG Lee, JS Park, JY Oh, KC Chung, H An, HS Chu, BG Son, SH Kim. Front Aging Neurosci. 2023 Apr 12;15:1148444. doi: 10.3389/fnagi.2023.1148444. eCollection 2023.
2.Role of NCKAP1 in the Defective Phagocytic Function of Microglia-Like Cells Derived from Rapidly Progressing Sporadic ALS. MY Noh , MS Kwon, KW Oh, MY Nahm, JS Park, YE Kim, CS Ki, HK Jin, JS Bae, SH Kim. Mol Neurobiol. 2023 Aug;60(8):4761-4777. doi: 10.1007/s12035-023-03339-2.
3.Clinical and genetic characteristics of amyotrophic lateral sclerosis patients with ANXA11 variants. WJ Sung, MY Nahm, SM Lim, MY Noh, SG Lee, SM Hwang, YH Kim, JS Park, KW Oh, CS Ki, YE Kim, SH Kim. Brain Commun. 2022 Nov 16;4(6):fcac299. doi:10.1093/braincomms/fcac299. eCollection 2022.
4.Gelsolin variant amyloidosis mimicking progressive bulbar palsy. JS Park, YE Kim, KW Oh, MY Nahm, YJ Kim, MJ Kim, SH Kim. Muscle Nerve. 2022 Nov;66(5):E28-E30. doi:10.1002/mus.27714. Epub 2022 Sep 21.
5.Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. JY Nam, TY Lee, K Kim, S Chun, MS Kim, JH Shin , JJ Sung, BJ Kim, BJ Kim, KW Oh, KS Kim, SH Kim. Trials. 2022 18;23(1):415. doi: 10.1186/s13063-022-06327-